A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE H...

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-004508-21

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE ESTUDO MULTICÊNTRICO DE FASE 3, ALEATORIZADO, EM DUPLA OCULTAÇÃO, CONTROLADO POR PLACEBO SOBRE A EFICÁCIA ANALGÉSICA E A SEGURANÇA DA ADMINISTRAÇÃO SUBCUTÂNEA DE TANEZUMAB EM DOENTES COM OSTEOARTRITE DA ANCA OU DO JOELHO

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

•Demonstrate superior efficacy of tanezumab 5 mg and 2.5 mg administered subcutaneously (SC) every 8 weeks versus placebo at Week 24.


Critère d'inclusion

  • Osteoarthritis of the hip or knee